The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication
Madeline Loffredo, Hector Lucero, Da-Yuan Chen, Aoife O’connell, Simon Bergqvist, Ahmad Munawar, Asanga Bandara, Steff De Graef, Stephen D Weeks, Florian Douam, Mohsan Saeed, Ali H Munawar
Scientific Reports, doi:10.1038/s41598-021-84782-w
The lack of coronavirus-specific antiviral drugs has instigated multiple drug repurposing studies to redirect previously approved medicines for the treatment of SARS-CoV-2, the coronavirus behind the ongoing COVID-19 pandemic. A recent, large-scale, retrospective clinical study showed that famotidine, when administered at a high dose to hospitalized COVID-19 patients, reduced the rates of intubation and mortality. A separate, patient-reported study associated famotidine use with improvements in mild to moderate symptoms such as cough and shortness of breath. While a prospective, multi-center clinical study is ongoing, two parallel in silico studies have proposed one of the two SARS-CoV-2 proteases, 3CL pro or PL pro , as potential molecular targets of famotidine activity; however, this remains to be experimentally validated. In this report, we systematically analyzed the effect of famotidine on viral proteases and virus replication. Leveraging a series of biophysical and enzymatic assays, we show that famotidine neither binds with nor inhibits the functions of 3CL pro and PL pro . Similarly, no direct antiviral activity of famotidine was observed at concentrations of up to 200 µM, when tested against SARS-CoV-2 in two different cell lines, including a human cell line originating from lungs, a primary target of COVID-19. These results rule out famotidine as a direct-acting inhibitor of SARS-CoV-2 replication and warrant further investigation of its molecular mechanism of action in the context of COVID-19.
Author contributions
Competing interests The authors declare no competing interests.
References
Baez-Santos, Mielech, Deng, Baker, Mesecar, Catalytic function and substrate specificity of the papainlike protease domain of nsp3 from the Middle East respiratory syndrome coronavirus, J. Virol,
doi:10.1128/JVI.01294-14Boulware, A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2016638Carsana, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study, Lancet Infect. Dis,
doi:10.1016/S1473-3099(20)30434-5Corman, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill,
doi:10.2807/1560-7917Freitas, Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease, ACS Infect. Dis,
doi:10.1021/acsinfecdis.0c00168Jacobs, Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease, J. Med. Chem,
doi:10.1021/jm301580nJacobs, Probe Reports from the NIH Molecular Libraries Program
Kallal, Lee, Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy, West. J. Med
Keithley, Histamine H2-receptor antagonists, Nurs Clin North Am
Kirch, Halabi, Linde, Santos, Ohnhaus, Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements, Gastroenterology,
doi:10.1016/0016-5085(89)90503-9Lu, Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease, J. Med. Chem,
doi:10.1021/jm060207oMa, Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea, Eye,
doi:10.1038/s41433-020-0939-4Marshall, Portales-Cervantes, Leong, Mast cell responses to viruses and pathogen products, Int. J. Mol. Sci,
doi:10.3390/ijms20174241Muramatsu, SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.1601327113Ogando, SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, J. Gen. Virol,
doi:10.1099/jgv.0.001453Palacio-Rodriguez, Lans, Cavasotto, Cossio, Exponential consensus ranking improves the outcome in docking and receptor ensemble docking, Sci. Rep,
doi:10.1038/s41598-019-41594-3Ratia, A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.0805240105Sun, Li, Yates, Fernig, SimpleDSFviewer: a tool to analyze and view differential scanning fluorimetry data for characterizing protein thermal stability and interactions, Protein Sci,
doi:10.1002/pro.3703Thangam, The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets, Front. Immunol,
doi:10.3389/fimmu.2018.01873Tian, Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol,
doi:10.1016/S1470-2045(20)30309-0Tomar, Ligand-induced dimerization of middle east respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals, J. Biol. Chem,
doi:10.1074/jbc.M115.651463Van Hemert, SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro, PLoS Pathog,
doi:10.1371/journal.ppat.1000054Wu, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B,
doi:10.1016/j.apsb.2020.02.008Xie, A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19,
doi:10.1101/2020.06.22.165712Yang, Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study, Lancet Oncol,
doi:10.1016/S1470-2045(20)30310-7Zarnegar, Influenza infection in mice induces accumulation of lung mast cells through the recruitment and maturation of mast cell progenitors, Front. Immunol,
doi:10.3389/fimmu.2017.00310Zhang, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors, Science,
doi:10.1126/science.abb3405
